PAMALA MCGOWAN: Open Payments
NPI 1962019653 · MEXIA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$326 in 15 payments from 8 companies in 2025. Trend: 2023 $82 · 2024 $101 · 2025 $326
Food & beverage: $326
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| GlaxoSmithKline, LLC. | 2 | $47 |
| Novo Nordisk Inc | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $36 |
| Lilly USA, LLC | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
Products named: VRAYLAR, CAPLYTA, TRELEGY ELLIPTA, Wegovy, VAXNEUVANCE, MOUNJARO, Ozempic, BREZTRI.
Industry payments across TX — which companies pay providers there.
